A-FIB
MCID: ATR011
MIFTS: 66

Atrial Fibrillation (A-FIB)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Atrial Fibrillation

MalaCards integrated aliases for Atrial Fibrillation:

Name: Atrial Fibrillation 12 36 29 54 6 42 3 43 15 62 62 17 71
Fibrillation, Atrial 39
a-Fib 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060224
KEGG 36 H00731
ICD9CM 34 427.31
MeSH 43 D001281
NCIt 49 C50466
SNOMED-CT 67 49436004
UMLS 71 C0004238

Summaries for Atrial Fibrillation

PubMed Health : 62 About atrial fibrillation: Atrial fibrillation (A-tre-al fi-bri-LA-shun), or AF, is the most common type of arrhythmia (ah-RITH-me-ah). An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. AF occurs if rapid, disorganized electrical signals cause the heart's two upper chambers—called the atria (AY-tree-uh)—to fibrillate. The term "fibrillate" means to contract very fast and irregularly. In AF, blood pools in the atria. It isn't pumped completely into the heart's two lower chambers, called the ventricles (VEN-trih-kuls). As a result, the heart's upper and lower chambers don't work together as they should. People who have AF may not feel symptoms. However, even when AF isn't noticed, it can increase the risk of stroke. In some people, AF can cause chest pain or heart failure, especially if the heart rhythm is very rapid. AF may happen rarely or every now and then, or it may become an ongoing or long-term heart problem that lasts for years.

MalaCards based summary : Atrial Fibrillation, also known as fibrillation, atrial, is related to familial atrial fibrillation and long qt syndrome 10, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Atrial Fibrillation is KCNQ1 (Potassium Voltage-Gated Channel Subfamily Q Member 1), and among its related pathways/superpathways are Vascular smooth muscle contraction and Adrenergic signaling in cardiomyocytes. The drugs carbamide peroxide and Imiquimod have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A heart conduction disease that is characterized by uncoordinated electrical activity in the heart's upper chambers (the atria), which causes the heartbeat to become fast and irregular and has symptoms palpitations, weakness, fatigue, lightheadedness, dizziness, confusion, shortness of breath and chest pain.

MedlinePlus : 42 An arrhythmia is a problem with the speed or rhythm of the heartbeat. Atrial fibrillation (AF) is the most common type of arrhythmia. The cause is a disorder in the heart's electrical system. Often, people who have AF may not even feel symptoms. But you may feel Palpitations -- an abnormal rapid heartbeat Shortness of breath Weakness or difficulty exercising Chest pain Dizziness or fainting Fatigue Confusion AF can lead to an increased risk of stroke. In many patients, it can also cause chest pain, heart attack, or heart failure. Doctors diagnose AF using family and medical history, a physical exam, and a test called an electrocardiogram (EKG), which looks at the electrical waves your heart makes. Treatments include medicines and procedures to restore normal rhythm. NIH: National Heart, Lung, and Blood Institute

CDC : 3 Atrial fibrillation, often called AFib or AF, is the most common type of heart arrhythmia. An arrhythmia is when the heart beats too slowly, too fast, or in an irregular way. When a person has AFib, the normal beating in the upper chambers of the heart (the two atria) is irregular, and blood doesn't flow as well as it should from the atria to the lower chambers of the heart (the two ventricles). AFib may occur in brief episodes, or it may be a permanent condition.

KEGG : 36 Atrial fibrillation (AF, ATFB) is the most common cardiac arrhythmia and is regarded generally as a sporadic, acquired disorder. Nevertheless, recent growing evidence points to an important heritable basis for AF. By linkage analysis, several loci have been mapped for monogenetic AF. Some of these loci encode for subunits of potassium channels.

Wikipedia : 74 Atrial fibrillation (AF or A-fib) is an abnormal heart rhythm (arrhythmia) characterized by the rapid... more...

Related Diseases for Atrial Fibrillation

Diseases in the Atrial Fibrillation family:

Atrial Fibrillation, Familial, 3 Atrial Fibrillation, Familial, 1
Atrial Fibrillation, Familial, 2 Atrial Fibrillation, Familial, 4
Atrial Fibrillation, Familial, 5 Atrial Fibrillation, Familial, 6
Atrial Fibrillation, Familial, 7 Atrial Fibrillation, Familial, 8
Atrial Fibrillation, Familial, 9 Atrial Fibrillation, Familial, 10
Atrial Fibrillation, Familial, 11 Atrial Fibrillation, Familial, 12
Atrial Fibrillation, Familial, 13 Atrial Fibrillation, Familial, 14
Atrial Fibrillation, Familial, 15 Atrial Fibrillation, Familial, 18
Familial Atrial Fibrillation

Diseases related to Atrial Fibrillation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 882)
# Related Disease Score Top Affiliating Genes
1 familial atrial fibrillation 35.0 SCN5A SCN4B SCN3B SCN2B SCN1B NUP155
2 long qt syndrome 10 34.6 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2 ANK2
3 mitral valve stenosis 33.7 NPPB NPPA ACE
4 sick sinus syndrome 33.6 SCN5A SCN3B SCN1B NPPA KCNQ1 KCNJ2
5 familial sick sinus syndrome 33.5 SCN5A HCN4
6 short qt syndrome 33.3 SCN5A SCN4B SCN3B SCN1B KCNQ1 KCNJ2
7 pure autonomic failure 33.1 NPPA ACE
8 cardiac arrhythmia, ankyrin-b-related 33.1 SCN5A SCN4B KCNQ1 KCNJ2 KCNH2 KCNE2
9 cardiac arrhythmia 33.0 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 ANK2
10 congestive heart failure 32.9 SCN5A NPPB NPPA KCNQ1 KCNJ2 KCNE2
11 mitral valve insufficiency 32.6 NPPB NPPA ACE
12 heart valve disease 32.6 NPPB NPPA ACE
13 mitral valve disease 32.5 NPPB NPPA ACE
14 atrial standstill 1 32.5 SCN5A SCN1B NPPB NPPA GJA5 ACE
15 heart disease 32.5 SCN5A NPPB NPPA KCNQ1 KCNJ2 KCNH2
16 syncope 32.5 SCN5A NPPA KCNQ1 KCNH2
17 ventricular fibrillation, paroxysmal familial, 1 32.5 SCN5A KCNQ1 KCNH2 KCNE2
18 atrioventricular block 32.4 SCN5A NPPB KCNQ1 KCNH2 KCNE2 HCN4
19 rheumatic heart disease 32.4 NPPB GJA5 ACE
20 pericardial effusion 32.3 NPPB NPPA ACE
21 lipoprotein quantitative trait locus 32.3 SCN5A NPPB NPPA KCNH2 ACE
22 wolff-parkinson-white syndrome 32.3 SCN5A NPPB KCNQ1 KCNJ2 KCNH2 KCNE2
23 cardiac conduction defect 32.3 SCN5A KCNQ1 KCNH2 ANK2
24 myocardial infarction 32.3 SCN5A NPPB NPPA MYL4 ACE ABCC9
25 acute myocardial infarction 32.3 NPPB NPPA MYL4 ACE
26 progressive familial heart block, type ia 32.2 SCN5A GJA5 ANK2
27 atrial heart septal defect 32.2 SCN5A NPPB NPPA HCN4 GJA5 ACE
28 hypertrophic cardiomyopathy 32.1 SCN5A NPPB NPPA KCNQ1 KCNJ2 KCNH2
29 sinoatrial node disease 32.1 SCN5A SCN3B SCN1B KCNQ1 KCNJ2 KCNH2
30 pulmonary embolism 32.1 NPPB NPPA ACE
31 systolic heart failure 32.0 NPPB NPPA ACE
32 left bundle branch hemiblock 32.0 SCN5A NPPB ACE
33 cardiac arrest 31.9 SCN5A NPPB KCNQ1 KCNH2 HCN4 ANK2
34 hypertensive heart disease 31.9 NPPB NPPA ACE
35 dilated cardiomyopathy 31.9 SCN5A SCN4B SCN2B NPPB NPPA KCNQ1
36 pulmonary edema 31.8 NPPB NPPA ACE
37 patent foramen ovale 31.7 NPPB GJA5 ACE
38 hypokalemia 31.7 KCNQ1 KCNH2 ACE
39 long qt syndrome 31.7 SCN5A SCN4B SCN1B KCNQ1 KCNJ2 KCNH2
40 central sleep apnea 31.7 NPPB NPPA ACE
41 brugada syndrome 31.6 SCN5A SCN4B SCN3B SCN2B SCN1B NUP155
42 right bundle branch block 31.6 SCN5A SCN3B SCN2B SCN1B NPPB KCNH2
43 aortic valve disease 2 31.6 NPPB NPPA MYL4 ACE
44 atrial standstill 31.5 SCN5A NPPA GJA5
45 diastolic heart failure 31.5 NPPB NPPA ACE
46 second-degree atrioventricular block 31.4 SCN5A SCN3B HCN4
47 first-degree atrioventricular block 31.4 SCN5A NPPB KCNJ2 ACE
48 familial long qt syndrome 31.3 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2
49 third-degree atrioventricular block 31.3 SCN5A NPPB KCNJ2 KCNH2 HCN4 GJA5
50 tetralogy of fallot 31.3 SCN5A NPPB NPPA KCNH2 GJA5 ACE

Graphical network of the top 20 diseases related to Atrial Fibrillation:



Diseases related to Atrial Fibrillation

Symptoms & Phenotypes for Atrial Fibrillation

UMLS symptoms related to Atrial Fibrillation:


edema, chest pain, angina pectoris

GenomeRNAi Phenotypes related to Atrial Fibrillation according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.53 MYL4
2 Decreased viability GR00249-S 9.53 ABCC9 GJA5 KCNE2 MYL4 NPPA SCN1B
3 Decreased viability GR00402-S-2 9.53 KCNE2 KCNJ2 KCNQ1 NPPA NUP155 SCN1B

MGI Mouse Phenotypes related to Atrial Fibrillation:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.77 ABCC9 ACE GJA5 HCN4 KCNA5 KCNH2
2 muscle MP:0005369 9.32 ABCC9 GJA5 HCN4 KCNA5 KCNH2 KCNJ2

Drugs & Therapeutics for Atrial Fibrillation

PubMed Health treatment related to Atrial Fibrillation: 62

Treatment for atrial fibrillation (AF) depends on how often you have symptoms, how severe they are, and whether you already have heart disease . General treatment options include medicines, medical procedures, and lifestyle changes.

Drugs for Atrial Fibrillation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 499)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
carbamide peroxide Approved Phase 4 124-43-6
2
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
3
Atorvastatin Approved Phase 4 134523-00-5 60823
4
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
5
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
6
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
7
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
8
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
9 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
10
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
11
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
12
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
13
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
14
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
15
Propranolol Approved, Investigational Phase 4 525-66-6 4946
16
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
17
Histamine Approved, Investigational Phase 4 51-45-6 774
18
Antazoline Approved Phase 4 91-75-8 2200
19
Terazosin Approved Phase 4 63590-64-7 5401
20
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
21
Procainamide Approved Phase 4 51-06-9 4913
22
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
23
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
24 fluindione Approved, Investigational Phase 4 957-56-2
25
Phenindione Approved, Investigational Phase 4 83-12-5 4760
26
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
27
Ramipril Approved Phase 4 87333-19-5 5362129
28
Ezetimibe Approved Phase 4 163222-33-1 150311
29
Nifedipine Approved Phase 4 21829-25-4 4485
30
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
31
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
32
Pantoprazole Approved Phase 4 102625-70-7 4679
33
Dipyridamole Approved Phase 4 58-32-2 3108
34
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
35
Metolazone Approved Phase 4 17560-51-9 4170
36
Tolvaptan Approved Phase 4 150683-30-0 216237
37
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
38
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
39
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
40
AT-101 Approved, Investigational Phase 4 652-67-5, 90141-22-3 12597
41
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
42
Zinc Approved, Investigational Phase 4 7440-66-6 32051
43
Nitric Oxide Approved Phase 4 10102-43-9 145068
44
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
45
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
46 Bemiparin Approved, Investigational Phase 4 91449-79-5
47
Cefpirome Approved Phase 4 84957-29-9 5479539
48
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
49
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
50
Polyestradiol phosphate Approved Phase 4 28014-46-2

Interventional clinical trials:

(show top 50) (show all 2965)
# Name Status NCT ID Phase Drugs
1 Intensive Statin Therapy Effect on Incidence of Post-Operative Atrial Fibrillation Unknown status NCT02029534 Phase 4 Atorvastatin 20 mg;Atorvastatin 80 mg
2 Low Dose of Diltiazem for Rate Control of Atrial Fibrillation Unknown status NCT00834925 Phase 4 low dose diltiazem
3 The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
4 A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation Unknown status NCT02549963 Phase 4 Rivaroxaban
5 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial Unknown status NCT00724581 Phase 4 Amiodarone
6 Randomized Study Comparing Cardioversion vs. Catheter Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196209 Phase 4
7 Comparison of Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran in Patients With Non-valvular Atrial Fibrillation (RIVAL-AF Study) -Multicenter Randomized Study- Unknown status NCT02331602 Phase 4 Rivaroxaban;Dabigatran
8 Effects of Vernakalant and Flecainide on Atrial Contractility in Patients With Atrial Fibrillation Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
9 Linear Anatomically Versus Focal Electrophysiologically Guided Substrate Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
10 Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study 2 Unknown status NCT01504451 Phase 4
11 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
12 Atrial Fibrillation Therapy: A Multi-Center Clinical Study Unknown status NCT01341353 Phase 4 Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
13 Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing: Program for the Identification of 'Actionable' AF (PIAAF) Rx Study Unknown status NCT03126214 Phase 4 Anticoagulants
14 Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
15 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
16 Efficacy and Safety of Non-vitamin K Oral Anticoagulants and Vitamin K Oral Anticoagulants on Some Metabolic and Coagulation Parameters in Diabetic and Nondiabetic Patients With First Diagnosis of Non-valvular Atrial Fibrillation Unknown status NCT02935855 Phase 4 Dabigatran;Apixaban;Rivaroxaban;Edoxaban;Warfarin;Acenocumarole
17 Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients With Persistent Atrial Fibrillation Unknown status NCT00613496 Phase 4 irbesartan;placebo
18 The Study of Rosuvastatin for Reduction of Postoperative Paroxysmal Atrial Fibrillation in Patient Undergoing Radiofrequency Catheter Ablation Unknown status NCT02502110 Phase 4 rosuvastatin
19 A Nationwide Multicenter Trial Assessing the Effects of Catheter Ablation on Burden of Atrial Fibrillation Recorded by Implantable Cardiac Monitor Unknown status NCT02639793 Phase 4
20 Safety and Efficacy of Transvenous Pulmonary Isolation for the Treatment of Atrial Fibrillation: A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
21 A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent Atrial Fibrilation Unknown status NCT02389218 Phase 4 sequential drug adjustment (propafenone, sotalol or flecainide)
22 APixaban Versus PhenpRocoumon: Oral AntiCoagulation Plus Antiplatelet tHerapy in Patients With Acute Coronary Syndrome and Atrial Fibrillation Unknown status NCT02789917 Phase 4
23 Dronedarone in Pacemaker Patients With Paroxysmal Atrial Fibrillation Unknown status NCT01070667 Phase 4 Dronedarone;Placebo
24 Atrial Fibrillation and Pericardial Drainage: Incidence of Postoperative Atrial Fibrillation According to the Type of Mediastinal Drainage Catheters Unknown status NCT02808897 Phase 4
25 Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study) Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
26 Rate Control in Atrial Fibrillation: A Randomized, Double-Blind, Crossover Comparison of Carvedilol and Metoprolol Tartrate Unknown status NCT02251509 Phase 4 Carvedilol;Metoprolol tartrate
27 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
28 Comparison of a Rhythm Control Treatment Strategy Versus a Rate Control Strategy in Patients With Permanent or Long-term Persistent Atrial Fibrillation and Heart Failure Treated With Cardiac Resynchronization Therapy - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
29 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
30 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
31 Catheter Ablation for Atrial Fibrillation: A Multicenter Clinical Trial Unknown status NCT01113294 Phase 4
32 Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control Unknown status NCT02025465 Phase 4 Metoprolol;Diltiazem
33 Phase Ⅳ Study of CARTO 3D Mapping System vs Conventional Method in AF & VT Unknown status NCT00959205 Phase 4
34 Additional Linear Ablation Perpendicular to the Pulmonary Vein Isolation Line Reduces the Recurrence Rate of Paroxysmal Atrial Fibrillation (ALA-PAF) Unknown status NCT02637453 Phase 4
35 PV-Isolation for Paroxysmal Atrial Fibrillation: Isolation of the Arrhythmogenic Vein(s) vs. Isolation of All Veins Unknown status NCT00605748 Phase 4
36 The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement Unknown status NCT03183843 Phase 4 Dabigatran Etexilate;Warfarin
37 Left Atrial Ablation for Paroxysmal Atrial Fibrillation and Hypertension With Implantable Loop Recorder With or Without ROX Coupler Follow Up Study: The LAAPITUP 3 Study Unknown status NCT02243891 Phase 4
38 Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients Unknown status NCT01461434 Phase 4
39 "Bidirectional Conduction Block of Left Atrial Anterior Line in Patients With Left Atrial Ablation - Reduction of RF Applications Using the Thermocool SmartTouch Contact Force Sensing Catheter Unknown status NCT02217657 Phase 4
40 Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial Unknown status NCT02206815 Phase 4 Ticagrelor+Warfarin;Clopidogrel+Aspirin+Warfarin
41 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
42 A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers Unknown status NCT00161551 Phase 4
43 Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation: A Prospective 2-Centre Randomized Controlled Clinical Study (POWDER-AF) Unknown status NCT02475642 Phase 4
44 A Randomized, Prospective Multicenter Pilot Study to Determine the Influence of the Ventricular Pacing Site on the Incidence of Atrial Fibrillation and Heart Failure in Patients With Indication for Permanent Pacemaker Stimulation Therapy. Unknown status NCT00292383 Phase 4
45 AMIOCAAF (AMIOdarone vs. Catheter Ablation for Prevention of Recurrent Symptomatic Atrial Fibrillation): a Randomized Controlled Trial - Vanguard Phase Unknown status NCT02341105 Phase 4 Amiodarone
46 EvaluAtion of Predictive Value of Multisite Intracardiac EchoCardiography During Imaging of Structure and funCTION of Left Atrial Appendage in Comparison to Transesophageal Echocardiography Unknown status NCT01371279 Phase 4
47 COR HF - Clinical Benefits in Optimized Remote HF Patient Management Unknown status NCT01482598 Phase 4
48 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
49 A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure Unknown status NCT03088072 Phase 4 Edoxaban;Aspirin and Clopidogrel;Aspirin and Warfarin
50 IntAct, Study on Promotion of Intrinsic Activity. Unknown status NCT00156741 Phase 4

Search NIH Clinical Center for Atrial Fibrillation

Inferred drug relations via UMLS 71 / NDF-RT 50 :


anisindione
Atenolol
Deslanoside
Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Diltiazem
Diltiazem Hydrochloride
Diltiazem maleate
Disopyramide
Disopyramide Phosphate
DITIAZ
dofetilide
ibutilide
ibutilide fumarate
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Procainamide
Procainamide Hydrochloride
Propafenone
Propafenone Hydrochloride
Quinidine
quinidine gluconate
quinidine polygalacturonate
Quinidine Sulfate
Sotalol
Sotalol Hydrochloride
Verapamil
Verapamil hydrochloride
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Cochrane evidence based reviews: atrial fibrillation

Genetic Tests for Atrial Fibrillation

Genetic tests related to Atrial Fibrillation:

# Genetic test Affiliating Genes
1 Atrial Fibrillation 29

Anatomical Context for Atrial Fibrillation

MalaCards organs/tissues related to Atrial Fibrillation:

40
Heart, Kidney, Testes, Brain, Lung, Endothelial, Thyroid

Publications for Atrial Fibrillation

Articles related to Atrial Fibrillation:

(show top 50) (show all 30471)
# Title Authors PMID Year
1
HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). 6
21810866 2011
2
Periprocedural Management of Oral Anticoagulation. 42
32505262 2020
3
Early versus delayed cardioversion: why should we wait? 42
32164464 2020
4
Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions. 42
32066285 2020
5
Thrombolysis with alteplase for acute ischemic stroke patients with atrial fibrillation. 61 54
20483000 2010
6
Association of ADRB1 gene polymorphism with atrial fibrillation. 61 54
20384459 2010
7
Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. 61 54
20170814 2010
8
Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. 54 61
20117462 2010
9
Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. 54 61
20083826 2010
10
[Role of ACE-inhibitors in preventing atrial fibrillation relapses in normotensive patients]. 61 54
20066882 2009
11
[Associations of the genetic polymorphisms in CYP11B2 gene with nonfamilial structural atrial fibrillation]. 54 61
20193392 2009
12
Genetic polymorphism of KCNH2 confers predisposition of acquired atrial fibrillation in Chinese. 61 54
19490382 2009
13
Predicting successful pulmonary vein isolation in patients with atrial fibrillation by brain natriuretic Peptide plasma levels. 61 54
19763191 2009
14
Utility of brain natriuretic peptide as a predictor of atrial fibrillation after cardiac operations. 54 61
19699901 2009
15
Mutation in the S3 segment of KCNQ1 results in familial lone atrial fibrillation. 54 61
19632626 2009
16
Comprehensive mutation scanning of LMNA in 268 patients with lone atrial fibrillation. 61 54
19427440 2009
17
Study of the factors related to atrial fibrillation after coronary artery bypass grafting: a search for a marker to predict the occurrence of atrial fibrillation before surgical intervention. 54 61
19327514 2009
18
Effects of exercise testing on natriuretic peptide secretion in patients with atrial fibrillation. 54 61
19378231 2009
19
Does treatment of hypertension decrease the incidence of atrial fibrillation and cardioembolic stroke? 61 54
19327599 2009
20
Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion. 61 54
18201783 2009
21
Functional polymorphisms in ACE and CYP11B2 genes and atrial fibrillation in patients with hypertensive heart disease. 61 54
19117407 2009
22
Brain natriuretic peptide correlates with the extent of atrial fibrillation-associated silent brain lesions. 61 54
18823968 2008
23
Letter by Hong et al regarding article, "Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation". 61 54
18852373 2008
24
A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. 54 61
18929244 2008
25
Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. 61 54
18794401 2008
26
Progeria caused by a rare LMNA mutation p.S143F associated with mild myopathy and atrial fibrillation. 54 61
18339564 2008
27
Plasma B-type natriuretic peptide predicts atrial fibrillation during rehabilitation after cardiac surgery. 61 54
18677172 2008
28
Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure. 54 61
18638595 2008
29
Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillation. 54 61
18598963 2008
30
Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. 54 61
18614783 2008
31
[Clinical characteristics of patients with persistent atrial fibrillation referred for cardioversion: Spanish Cardioversion Registry (REVERSE)]. 54 61
18570785 2008
32
[The incidence and predictors of atrial fibrillation in hypertrophic cardiomyopathy]. 54 61
19040064 2008
33
Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population. 61 54
18496132 2008
34
X-linked nonsyndromic sinus node dysfunction and atrial fibrillation caused by emerin mutation. 54 61
18266676 2008
35
ACE inhibitors as antifibrotic agents in atrial fibrillation: potential relevance in cardiac surgery. 61 54
18495720 2008
36
Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. 54 61
18378609 2008
37
Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. 54 61
18215703 2008
38
Potential use of statins to prevent atrial fibrillation after coronary artery bypass surgery. 61 54
18198239 2008
39
N-terminal pro B-type natriuretic peptide levels predict newly detected atrial fibrillation in a population-based cohort. 61 54
18345329 2008
40
Brain natriuretic peptide as a surrogate marker for cardioembolic stroke with paroxysmal atrial fibrillation. 61 54
18799875 2008
41
Natriuretic peptides in patients with atrial fibrillation. 54 61
19039756 2008
42
KCNQ1 mutation Q147R is associated with atrial fibrillation and prolonged QT interval. 54 61
17997361 2007
43
Postinterventional medication after catheter ablation of atrial fibrillation: angiotensin receptor blockers or ACE inhibitors? 54 61
18035920 2007
44
Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features. 61 54
17875969 2007
45
Plasma brain natriuretic peptide level after radiofrequency catheter ablation of paroxysmal, persistent, and permanent atrial fibrillation. 54 61
17670784 2007
46
Candesartan in the prevention of relapsing atrial fibrillation. 61 54
17113170 2007
47
Inefficiency of renin-angiotensin inhibitors in preventing atrial fibrillation in patients with a normal heart. 54 61
17534249 2007
48
Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. 61 54
17556195 2007
49
Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure. 61 54
16919342 2007
50
Post-cardiothoracic surgery atrial fibrillation: a review of preventive strategies. 61 54
17374620 2007

Variations for Atrial Fibrillation

ClinVar genetic disease variations for Atrial Fibrillation:

6 (show all 42) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KCNQ1 NM_181798.1(KCNQ1):c.37A>G (p.Ser13Gly)SNV Pathogenic 3143 rs120074192 11:2549189-2549189 11:2527959-2527959
2 SCN5A NM_000335.4(SCN5A):c.1410C>G (p.Asn470Lys)SNV Pathogenic 30047 rs199473115 3:38646328-38646328 3:38604837-38604837
3 KCNQ1 NM_181798.1(KCNQ1):c.244T>C (p.Ser82Pro)SNV Pathogenic 67094 rs199472705 11:2592575-2592575 11:2571345-2571345
4 KCNQ1 NM_181798.1(KCNQ1):c.40G>A (p.Val14Met)SNV Pathogenic/Likely pathogenic 67072 rs199472687 11:2549192-2549192 11:2527962-2527962
5 SCN5A NM_198056.2(SCN5A):c.5624T>C (p.Met1875Thr)SNV Likely pathogenic 68002 rs199473324 3:38592239-38592239 3:38550748-38550748
6 SNTA1 NM_003098.2(SNTA1):c.1169C>T (p.Ala390Val)SNV Likely pathogenic 8476 rs121434500 20:31998009-31998009 20:33410203-33410203
7 KCNE2 NM_172201.1(KCNE2):c.79C>T (p.Arg27Cys)SNV Conflicting interpretations of pathogenicity 6055 rs74315449 21:35742856-35742856 21:34370557-34370557
8 SCN5A NM_198056.2(SCN5A):c.1963G>A (p.Glu655Lys)SNV Conflicting interpretations of pathogenicity 30049 rs199473579 3:38640469-38640469 3:38598978-38598978
9 KCNJ2 NM_000891.2(KCNJ2):c.277G>A (p.Val93Ile)SNV Conflicting interpretations of pathogenicity 30121 rs147750704 17:68171457-68171457 17:70175316-70175316
10 SCN5A NM_198056.2(SCN5A):c.5851G>A (p.Val1951Met)SNV Conflicting interpretations of pathogenicity 68014 rs41315493 3:38592012-38592012 3:38550521-38550521
11 SCN5A NM_198056.2(SCN5A):c.4478A>G (p.Lys1493Arg)SNV Conflicting interpretations of pathogenicity 67898 rs199473260 3:38597211-38597211 3:38555720-38555720
12 SCN5A NM_198056.2(SCN5A):c.5476C>T (p.Arg1826Cys)SNV Conflicting interpretations of pathogenicity 67994 rs199473635 3:38592387-38592387 3:38550896-38550896
13 TTN NM_001267550.2(TTN):c.101212C>T (p.Arg33738Cys)SNV Conflicting interpretations of pathogenicity 47633 rs56273463 2:179400130-179400130 2:178535403-178535403
14 TTN NM_001267550.2(TTN):c.9359G>A (p.Arg3120Gln)SNV Conflicting interpretations of pathogenicity 47636 rs72647894 2:179632598-179632598 2:178767871-178767871
15 TTN NM_001267550.2(TTN):c.18776C>G (p.Thr6259Ser)SNV Conflicting interpretations of pathogenicity 46644 rs72648949 2:179594107-179594107 2:178729380-178729380
16 TTN NM_001267550.2(TTN):c.47315G>A (p.Arg15772Gln)SNV Conflicting interpretations of pathogenicity 47010 rs72677233 2:179482763-179482763 2:178618036-178618036
17 TTN NM_001267550.2(TTN):c.4359A>T (p.Arg1453Ser)SNV Conflicting interpretations of pathogenicity 47051 rs376857956 2:179642552-179642552 2:178777825-178777825
18 TTN NM_001267550.2(TTN):c.69130C>T (p.Pro23044Ser)SNV Conflicting interpretations of pathogenicity 47265 rs55980498 2:179441932-179441932 2:178577205-178577205
19 TTN NM_001267550.2(TTN):c.8902+14T>ASNV Conflicting interpretations of pathogenicity 137827 rs13388274 2:179634392-179634392 2:178769665-178769665
20 SCN5A NM_198056.2(SCN5A):c.3392C>T (p.Thr1131Ile)SNV Uncertain significance 67795 rs199473197 3:38618271-38618271 3:38576780-38576780
21 SCN5A NM_000335.4(SCN5A):c.414G>A (p.Met138Ile)SNV Uncertain significance 67865 rs199473060 3:38663959-38663959 3:38622468-38622468
22 SCN5A NM_000335.4(SCN5A):c.1282G>A (p.Glu428Lys)SNV Uncertain significance 30048 rs199473111 3:38647498-38647498 3:38606007-38606007
23 SCN5A NM_000335.5(SCN5A):c.5958C>A (p.Asn1986Lys)SNV Uncertain significance 30045 rs199473335 3:38591902-38591902 3:38550411-38550411
24 SCN5A NM_198056.2(SCN5A):c.1333C>G (p.His445Asp)SNV Uncertain significance 30046 rs199473112 3:38647447-38647447 3:38605956-38605956
25 HCN4 NM_005477.3(HCN4):c.2716G>A (p.Gly906Arg)SNV Uncertain significance 404123 rs373572497 15:73615718-73615718 15:73323377-73323377
26 MYH7 NM_000257.4(MYH7):c.5190G>T (p.Met1730Ile)SNV Uncertain significance 617741 rs1566522989 14:23884683-23884683 14:23415474-23415474
27 TTN NM_001267550.2(TTN):c.73391G>A (p.Arg24464Gln)SNV Uncertain significance 691684 2:179437468-179437468 2:178572741-178572741
28 TTN NM_001267550.2(TTN):c.57399A>C (p.Leu19133Phe)SNV Uncertain significance 691692 2:179462410-179462410 2:178597683-178597683
29 TTN NM_001267550.2(TTN):c.57356A>T (p.Lys19119Met)SNV Likely benign 691745 2:179462453-179462453 2:178597726-178597726
30 TTN NM_001267550.2(TTN):c.44014G>A (p.Asp14672Asn)SNV Likely benign 691748 2:179495761-179495761 2:178631034-178631034
31 TTN NM_001267550.2(TTN):c.42513T>A (p.His14171Gln)SNV Likely benign 691749 2:179498713-179498713 2:178633986-178633986
32 TTN NM_001267550.2(TTN):c.63976C>T (p.His21326Tyr)SNV Likely benign 691743 2:179451962-179451962 2:178587235-178587235
33 SCN5A NM_000335.5(SCN5A):c.5848G>T (p.Val1950Leu)SNV Benign/Likely benign 36765 rs41315493 3:38592012-38592012 3:38550521-38550521
34 HCN4 NM_005477.3(HCN4):c.2648C>G (p.Pro883Arg)SNV Benign/Likely benign 137542 rs148398509 15:73615786-73615786 15:73323445-73323445
35 TTN NM_001267550.2(TTN):c.87877C>T (p.Arg29293Cys)SNV Benign/Likely benign 47470 rs191482653 2:179422112-179422112 2:178557385-178557385
36 BAG3 NM_004281.4(BAG3):c.1138C>T (p.Pro380Ser)SNV Benign/Likely benign 162782 rs144692954 10:121436204-121436204 10:119676692-119676692
37 ANK2 NM_001148.6(ANK2):c.9854T>C (p.Ile3285Thr)SNV Benign/Likely benign 190528 rs36210417 4:114279628-114279628 4:113358472-113358472
38 AKAP9 NM_005751.4(AKAP9):c.139C>T (p.His47Tyr)SNV Benign/Likely benign 191549 rs35669569 7:91603115-91603115 7:91973801-91973801
39 BAG3 NM_004281.4(BAG3):c.187C>G (p.Pro63Ala)SNV Benign 178006 rs144041999 10:121429369-121429369 10:119669857-119669857
40 KCNH2 NM_000238.4(KCNH2):c.2690A>C (p.Lys897Thr)SNV Benign 67427 rs1805123 7:150645534-150645534 7:150948446-150948446
41 KCNE2 NM_172201.1(KCNE2):c.269A>G (p.Glu90Gly)SNV not provided 67617 rs199473366 21:35743046-35743046 21:34370747-34370747
42 KCNQ1 NM_181798.1(KCNQ1):c.59A>G (p.Gln20Arg)SNV not provided 67074 rs199472689 11:2549211-2549211 11:2527981-2527981

Expression for Atrial Fibrillation

Search GEO for disease gene expression data for Atrial Fibrillation.

Pathways for Atrial Fibrillation

Pathways related to Atrial Fibrillation according to KEGG:

36
# Name Kegg Source Accession
1 Vascular smooth muscle contraction hsa04270
2 Adrenergic signaling in cardiomyocytes hsa04261

Pathways related to Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 SCN5A SCN4B SCN3B SCN2B SCN1B GJA5
2
Show member pathways
12.84 KCNQ1 KCNJ2 KCNH2 KCNA5 HCN4 ABCC9
3
Show member pathways
12.48 SCN5A SCN4B SCN3B SCN2B SCN1B
4
Show member pathways
12.46 SCN5A SCN4B SCN3B SCN2B SCN1B NPPA
5
Show member pathways
12.45 SCN5A SCN4B SCN1B NPPB NPPA MYL4
6 12.23 KCNQ1 KCNJ2 KCNH2 KCNE2 KCNA5
7